Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan
Condition: Rheumatoid Arthritis Interventions: Drug: Methotrexate; Drug: Adalimumab Sponsors: Keio University; Eisai Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arthritis | Humira | Japan Health | Methotrexate | Research | Rheumatology | South Korea Health | Taiwan Health